Received Jan 28, 2026
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| HEP | HEP B (HEPLISAV-B) | DYNAVAX TECHNOLOGIES CORPORATION | 2 | 946062 | IM / RA |
Patient received second dose of series 26 days after first dose of the series, this series is supposed to be completed 1 month after 1st dose. Patient has been informed and reported no side effects
N/A
N/A
N/A
N/A
N/A